About Us
- Home
- About Us
- History
History
2025
-
01
- ASCA101: Ovarian Cancer Phase 2 IND submission to MFDS (KR)
2024
-
12
- ASCA101CC: Phase 2 IND approval MFDS (KR)
- Pre-IPO audit
-
11
- ASCA101CC: Phase 2 IND submission to MFDS (KR)
-
10
- Selected for Technology evaluation program (KHIDI, Korea Health Industry Development Institute)
- INNOBIZ certified
-
09
- ASCA101 Phase 1 clinical trial completed (US, KR)
-
01
- ASCA101CC: licensing agreement signed for Korean marketing rights
2023
-
06
- Application patent filed for ASCA101CC: cancer cachexia (US and KR)
-
01
- Venture Enterprise certification granted
2022
-
04
- Series B closed
-
02
- ASCA101 Phase 1 IND FDA approval (US)
2021
-
06
- ASCA101 Phase 1 IND MFDS approval (KR)
-
04
- ASCA101 Phase 1 IND submitted to MFDS (Ministry of Food and Drug Safety, Korea)
- ASCA101 GLP tox study completed
-
02
- ASCA101 substance patent registered in 6 countries (CN, JP, CA, AU, RU, MX)
2020
-
12
- GMP manufacturing completed
-
08
- Bridge funding closed
2019
-
10
- Company affiliated research center certified
-
07
- ASCA101 toxicity study initiated
-
01
- Venture Enterprise certified
- Series A closed
2018
-
09
- ASCA101 substance patent registered in KR
-
08
- MetaFines Co., Ltd. established